Human acellular vessel extra-cellular matrix clinical trials
How each study uses human acellular vessel extra-cellular matrix is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the human acellular vessel extra-cellular matrix studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 19 Dec 2024 · symvess · BLA 125812 (FDA, Purple Book)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2023 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test human acellular vessel extra-cellular matrix, phase 3 first.
- Jun 2027To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring HemodialysisPhase 3 · Humacyte, Inc.
Studies
Open first, then newest update. How each study uses human acellular vessel extra-cellular matrix is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Multicenter Study to Evaluate the Safety and Efficacy of SYMVESS™ in a Real World Setting in Patients With Extremity Arterial Injury Requiring Urgent RepairNot yet recruitingPhase 4Humacyte, Inc.NCT07762794Written as Acellular Tissue Engineered Vessel
- An Open-label Study to Assess the Safety and Efficacy of SYMVESS® as a Vascular Conduit in Adolescents With Extremity Arterial Injury.Not yet recruitingPhase 3Humacyte, Inc.NCT07762313Written as Acellular Tissue Engineered Vessel (Symvess)
- Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular TraumaCompletedPhase 2/3Humacyte, Inc.NCT03005418Written as Acellular Tissue Engineered Vessel (ATEV)
- To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring HemodialysisActive, not recruitingPhase 3Humacyte, Inc.NCT05908084Written as Acellular Tissue Engineered Vessel (ATEV)